Melanotan 1: What It Is, How It Works, and What the Evidence Actually Shows

What Is Melanotan 1 and How Does It Differ from Other Peptides?

Melanotan 1 is afamelanotide, a 13-amino-acid synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds selectively to the MC1R receptor on melanocytes, triggering eumelanin synthesis and producing a protective tan without requiring UV exposure. The EMA approved it in 2014 under the brand name Scenesse as a subcutaneous implant (16 mg, replaced every 60 days) specifically for adults with erythropoietic protoporphyria.

The peptide sits in a broader class of melanocortin analogues that are often grouped together in online communities, but they are pharmacologically distinct. Melanotan 2 is a cyclic analogue with lower MC1R selectivity and meaningful activity at MC3R and MC4R. AOD 9604 is an entirely separate peptide derived from the C-terminal end of human growth hormone. HGH Frag 176-191 overlaps structurally with AOD 9604 but refers to a slightly different numbering convention used in older literature. Myostatin inhibitors such as follistatin peptides work via the TGF-beta signalling pathway and share no mechanism with any melanocortin compound. Treating these as interchangeable is a clinical error.

MC1R Mechanism: Why Receptor Selectivity Matters

Afamelanotide achieves its effects by acting as a potent agonist at MC1R with a half-life of roughly 40 hours following implant dissolution, substantially longer than the minutes-long half-life of endogenous alpha-MSH [1]. MC1R activation phosphorylates cyclic AMP response elements inside melanocytes, upregulating tyrosinase, the rate-limiting enzyme in eumelanin production [2].

Selectivity is the reason Melanotan 1 has a cleaner safety signal than Melanotan 2. MC4R agonism drives penile erection, appetite suppression, and blood pressure changes. Because afamelanotide binds MC1R with roughly 10-fold greater affinity than MC4R, sexual side effects appear rarely in clinical datasets, whereas Melanotan 2 users report spontaneous erections in the majority of self-reported cases [3]. The FDA's pharmacology review of melanocortin compounds explicitly separates receptor-subtype activity as a key risk determinant [4].

Downstream, MC1R stimulation also has anti-inflammatory properties independent of pigmentation. Activation reduces NF-kB signalling and lowers interleukin-1beta release from keratinocytes, which helps explain the compound's protective effect against phototoxic pain in EPP beyond simple melanin shielding [5].

Clinical Evidence for Afamelanotide in EPP

Erythropoietic protoporphyria causes severe, sometimes disabling pain on minimal sunlight exposure due to accumulation of protoporphyrin IX in the skin. The key Phase III trial (CUV039, N=94) randomised EPP patients to afamelanotide 16 mg implant or placebo over six months [6]. Patients receiving afamelanotide gained a mean 26.4 additional minutes of pain-free direct sunlight per day compared with placebo (P<0.001). A second Phase III study conducted in North America (CUV030, N=74) replicated the benefit, with afamelanotide patients reporting 69.4 hours of pain-free sunlight over the six-month study period vs. 40.8 hours for placebo [7].

The European Medicines Agency's Committee for Medicinal Products for Human Use concluded: "The benefits of Scenesse outweigh its risks in adults with EPP. The most common side effects are implant-site reactions, nausea, and fatigue, which are generally mild and transient" [8].

Long-term open-label data from the ClinicalTrials registry (NCT01480362) tracking 115 patients over 36 months showed no new safety signals, no melanoma cases attributable to treatment, and stable dermatologic findings on serial photography [9]. These numbers matter because one of the most cited theoretical concerns about any tanning peptide is melanoma promotion. In the CUV039 and CUV030 datasets combined, investigators observed no statistically significant increase in dysplastic nevi formation [6, 7].

Melanotan 2 Risks: A Sharper Safety Conversation

Melanotan 2 is not approved by the FDA, the EMA, or any major regulatory body for any indication as of 2025 [10]. It is sold as a research chemical and administered by users subcutaneously, often from unverified lyophilised powder preparations. The risk profile differs from afamelanotide in three concrete ways.

First, MC4R agonism raises blood pressure. A pharmacokinetic challenge study in healthy volunteers recorded mean systolic increases of 8 mmHg within two hours of 0.01 mg/kg Melanotan 2 injection [11]. Second, the same MC4R pathway drives spontaneous erections (priapism risk) and nausea requiring ondansetron co-administration in a subset of users. Third, unregulated compounding means purity is unverified. A 2023 analysis published in the British Journal of Dermatology tested 27 black-market Melanotan 2 vials; 11 contained less than 80% of the stated peptide concentration and three contained detectable bacterial endotoxin [12].

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK issued a formal safety warning stating that Melanotan 2 "has not been tested for safety and has been associated with serious adverse effects including changes in moles, severe nausea and vomiting, and cardiovascular events" [13]. Clinicians should counsel patients that the risk-benefit calculation for Melanotan 2 is not the same as for the EMA-approved afamelanotide formulation.

AOD 9604: What the Data Actually Show

AOD 9604 is a 16-amino-acid peptide corresponding to amino acids 177-191 of human growth hormone, with an additional tyrosine residue added at the N-terminus to stabilise the sequence. It does not bind GH receptors or stimulate IGF-1 production. Its proposed mechanism is direct stimulation of beta-3 adrenergic receptors in adipose tissue, promoting lipolysis without the insulin-resistance effects associated with full-length GH [14].

The compound completed Phase IIb trials for obesity (the METAOD series, sponsored by Metabolic Pharmaceuticals). In METAOD005 (N=300), oral AOD 9604 1 mg daily for 12 weeks produced no statistically significant weight loss versus placebo, leading the sponsor to discontinue the obesity development programme [15]. The FDA granted AOD 9604 GRAS (Generally Recognised as Safe) status in 2014 for use as a food ingredient, but this designation does not constitute approval for therapeutic injection [16].

AOD 9604 is widely offered by compounding pharmacies as a weight-loss injection, often alongside semaglutide or tirzepatide. This combination is pharmacologically speculative. No randomised controlled trial has tested AOD 9604 by injection against placebo for human weight loss. The METAOD oral studies cannot be extrapolated to injectable dosing because bioavailability, receptor exposure, and adverse-effect kinetics differ substantially between routes. Clinicians prescribing it should document that patients understand the evidence gap.

HGH Fragment 176-191: Rodent Data Versus Human Reality

HGH Frag 176-191 refers to the same C-terminal region of growth hormone as AOD 9604, sometimes numbered differently based on whether the added N-terminal tyrosine is counted. In rodent models, this fragment reduced adipose mass by 50% over eight weeks at doses of 500 mcg/kg/day without affecting serum IGF-1 or glucose [17]. These results drove commercial interest.

The extrapolation to humans has not been validated. No published Phase II or Phase III randomised trial exists for HGH Frag 176-191 in human obesity. A single open-label pharmacokinetic study in six healthy volunteers measured detectable peptide levels up to four hours after a 500 mcg subcutaneous injection but did not measure body composition endpoints [18]. Rodent-to-human dose conversions using the standard FDA allometric scaling factor of 6.2 would require roughly 3 to 000 mcg per day in a 70 kg person to approximate rodent efficacy doses, far above the 500-2 to 000 mcg/day ranges commonly cited in peptide communities.

The FDA has not approved HGH Frag 176-191 for any indication. The agency's 2023 guidance on compounded peptides placed several unapproved GH fragments on a list of substances that may not be compounded under Section 503A or 503B because they have not been shown to be essentially a copy of an approved drug and lack adequate human safety data [19].

Myostatin Inhibitors: The Science and the Absent Approvals

Myostatin (GDF-8) is a TGF-beta superfamily member that limits skeletal muscle growth. Inhibiting it produces dramatic muscle hypertrophy in animal models. Cattle with natural myostatin mutations display the "double-muscling" phenotype, and myostatin-null mice gain 200-300% more muscle mass than wild-type controls [20].

Translating this to humans has proven difficult. ACE-031, a soluble activin receptor type IIB fusion protein developed by Acceleron Pharma, completed Phase II trials in Duchenne muscular dystrophy (DMD). The trial was halted in 2011 after participants developed epistaxis, telangiectasias, and gum bleeding attributed to off-target suppression of other TGF-beta ligands including BMP9, which regulates vascular integrity [21]. The lean mass gains were real (mean 4.9% over 12 weeks) but the vascular adverse events stopped development.

Follistatin gene therapy and peptide follistatin preparations are circulating in grey markets as myostatin inhibitors. Follistatin does suppress myostatin, but it also suppresses activin A, FSH, and multiple other TGF-beta ligands. A 2020 case series in JAMA Internal Medicine described three bodybuilders who self-administered follistatin 344 plasmid injections and developed polymyositis-like inflammatory myopathy [22]. No myostatin inhibitor has FDA or EMA approval for aesthetic or performance use as of 2025.

Comparing These Peptides Side by Side

All five compounds discussed here are distinct molecules with distinct targets. Afamelanotide has the strongest regulatory and evidence base: two Phase III trials, EMA approval, and a defined patient population. Melanotan 2 shares some afamelanotide activity but adds MC4R risk and lacks any regulatory approval. AOD 9604 has oral Phase IIb data showing no weight-loss benefit and no injectable RCT evidence. HGH Frag 176-191 has rodent lipolysis data and a single six-person PK study in humans. Myostatin inhibitors have the most dramatic animal data and the most concerning human adverse-event record.

For a clinician building a peptide protocol, the question is not which compound sounds most compelling but which compounds have human evidence in the specific indication being treated. The answer, for this class, is afamelanotide for EPP. Everything else sits at varying stages of preclinical or early clinical investigation without an approved therapeutic context.

Dosing, Administration, and Monitoring for Afamelanotide

In the approved EPP indication, afamelanotide is administered as a single 16 mg subcutaneous implant inserted under local anaesthesia every 60 days by a trained healthcare professional. The implant dissolves over approximately 60 days, providing sustained plasma concentrations in the 0.1-0.3 ng/mL range [6].

Patients should undergo a full-body skin examination before starting therapy and every six months thereafter, given the theoretical concern about accelerated growth of existing nevi in the setting of elevated melanocortin tone. The CUV039 protocol used standardised dermoscopy at baseline and months two, four, and six to document nevi changes [6]. No clinically significant changes were detected, but continuing surveillance is considered standard practice per the European EPP guidelines published by the European Porphyria Network [23].

Blood pressure monitoring before each implant is reasonable given the cardiovascular effects seen at higher MC receptor stimulation. Liver function tests are warranted at baseline because EPP itself can cause cholestatic liver disease, and distinguishing treatment effects from the underlying condition requires a documented baseline [24].

Common side effects reported across the CUV039 and CUV030 trials included nausea (21% afamelanotide vs. 10% placebo), fatigue (18% vs. 11%), and injection-site reactions (14% vs. 4%). Serious adverse events were rare and not significantly different between arms [7].

Regulatory Status Summary: What Can Be Prescribed

Afamelanotide (Scenesse) is approved in the European Union, Switzerland, Israel, and Australia for EPP in adults. In the United States, it received FDA Orphan Drug designation but has not received full NDA approval for commercial sale. As of 2025, it is available in the US only through Clinuvel Pharmaceuticals' managed access programme under Expanded Access / compassionate use pathways for confirmed EPP patients [25].

Melanotan 2, AOD 9604, HGH Frag 176-191, and myostatin inhibitor peptides such as follistatin are not approved by the FDA for any therapeutic indication. The FDA's 2023 guidance on bulk drug substances for compounding explicitly restricts compounding of peptides that lack adequate evidence of safety and efficacy in humans [19]. Physicians offering these compounds under a compounding pathway should be aware that federal enforcement posture toward unapproved peptides has tightened since 2021, with multiple warning letters issued to 503A pharmacies including letters referencing PT-141 (bremelanotide's precursor), BPC-157, and similar classes [26].